Calibrate vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent research·How we rank →

Visit MEDVi - our pick of these two→or find your match

Calibrate and MEDVi are tied at 7.7/10. MEDVi is more affordable at $179/mo vs $199/mo. Choose Calibrate for users who want a physician-led metabolic health program with. Choose MEDVi for users who want a low entry price with oral and injectable co.

A side-by-side look at Calibrate and MEDVi to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Calibrate

#19 of 52

7.7/10

Metabolic health company offering a physician-led GLP-1 program restructured in 2026: $199/mo with a 3-month minimum commitment (no more $1,649 one-time enrollment fee). Includes nutrition coaching, labs, a smart scale, and a 10%+ weight-loss guarantee with 50% money-back.

Visit Calibrate

MEDVi

#20 of 52

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Feature	Calibrate	MEDVi
Our Score	7.7/10	7.7/10
Starting Price	$199/mo	$179/mo
Medication Type	Both	Both
Insurance Accepted	Yes	No
Best For	Users who want a physician-led metabolic health program with a 3-month commitment and a weight-loss guarantee	Users who want a low entry price with oral and injectable compounded options
Ranking	#19	#20
Get started	Visit Calibrate	Visit MEDVi

Pros & Cons Compared

Calibrate

Pros

+2026 pricing rewrite, flat $199/mo with 3-month commitment ($597 upfront), then month-to-month. The old $1,649 one-time enrollment fee was removed.
+Board-certified physicians with metabolic health specialization lead treatment
+10%+ body-weight-loss guarantee with 50% money-back if not met
+Includes labs, nutrition coaching, personalized smart scale, and sleep/exercise support

Cons

−$597 upfront (3-month commitment) is a meaningful barrier vs. month-to-month competitors
−Medication cost is separate and varies significantly by payer route
−Fewer medications in the menu than larger marketplaces like Ro or Found
−Onboarding still takes 2-3 weeks to complete baseline labs and treatment plan

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Our Verdict

Calibrate and MEDVi are closely matched with identical scores of 7.7/10. If budget is your priority, MEDVi starts at $179/mo compared to Calibrate's $199/mo. Calibrate accepts insurance, which can significantly reduce your out-of-pocket costs. Choose Calibrate if you want: users who want a physician-led metabolic health program with a 3-month commitment and a weight-loss guarantee. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.

Still undecided? Editor's Featured Pick

TrimRx

$149/mo · 7.8/10 · Compounded

If neither Calibrate nor MEDVi feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is TrimRx. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $149/mo that stays the same at every dose.

Visit TrimRx→Read our full TrimRx review